Matthew L. Posard, Director at HALOZYME THERAPEUTICS, INC. (HALO), sold 18,996 shares at $106.13 ($2.0M) on 2026-09-16, disclosed to the SEC on 2026-09-17.
Scheduled sale ($2.0M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $106.13 | 3,100 | $329K | 16.1% |
| 2 | $106.83 | 3,000 | $320K | 15.7% |
| 3 | $108.04 | 8,896 | $961K | 47.0% |
| 4 | $108.99 | 4,000 | $436K | 21.3% |
| Total | $107.74 avg | 18,996 | $2.0M | 100% |
| Filing → |
| HALO | SELL | 2024-06-13 | $1.0M | — | Filing → |
| HALO | SELL | 2022-12-06 | $1.7M | — | Filing → |
| NAUT | BUY | 2021-12-01 | $226K | — | Filing → |